Further work will be needed to fully elucidate the role of ADAMTSs in controlling EGF bioavailability and downstream signalling in different cancer types and to establish whether this could lead to novel therapeutic strategies to prevent EGFR-driven tumorigenesis. Here, EGFR is linked to cancer.